We came across a bullish thesis on Arrowhead Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on ARWR. Arrowhead Pharmaceuticals, Inc.'s share was trading at $66.25 as of January 15th. ARWR’s trailing and forward P/E were 478.56 and 111.11 respectively according to Yahoo Finance.
[caption id="attachment_575379" align="aligncenter" width="750"]Arrowhead Pharmaceuticals is emerging as a leading RNAi-focused biotechnology company, anchored by its flagship...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.